Please assess the completion status of the following clinical trial:

Trial Title: Study of POMELLA™ Extract to Treat Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men 18 years or older (19 years in BC) with a histologic diagnosis of clinically localized prostate cancer prior to radical prostatectomy as defined by:~  1. Clinical state T1-T2~ 2. PSA \<20~ 3. Gleason score ≤ 7~* ECOG performance status of 0-1.~* Life expectancy greater than 10 years.~* Able to understand and give informed consent.~* Laboratory values must be as follows:~  1. White blood cell count: ≥ 3,000/mm\^3~ 2. Absolute granulocyte count: ≥ 1,500/mm\^3~ 3. Platelets: ≥ 100,000/mm\^3~ 4. Hemoglobin: ≥ 12g/dL~ 5. Serum creatinine: ≤ 1.5 x ULN~ 6. AST: ≤ 2 x ULN~ 7. ALT: ≤ 2 x ULN~ 8. Serum calcium: ≤ ULN~ 9. Total bilirubin: ≤ 1.5 x ULN~Exclusion Criteria:~* Patients who are receiving any other investigational therapy.~* Patients who have received or are receiving any other treatment for their prostate cancer.~* Patients with an active serious infection or other serious underlying medical condition that would otherwise impair their ability to receive protocol treatment.~* Dementia or significantly altered mental status that would prohibit the understanding and/or giving of informed consent.~* Histologic evidence of small cell carcinoma of the prostate.~* Patients who are currently receiving active therapy for other neoplastic disorders will not be eligible for study.~* Patients who are receiving any androgens, estrogens or progestational agents.~* Patients with a known hypersensitivity to pomegranates or composites of the capsules/placebo: hydroxypropyl methylcellulose, silicon dioxide or aerosol.~* Patients who are taking any drugs or natural health products which might impact biochemical tests (some examples include: spironolactone, aprepitant, bexarotene, clarithromycin, itraconazole, ketoconazole, St. John's wort). A washout period of 30 days prior to commencing the study would be necessary for these compounds if required.~* Patients who have chronic active hepatitis.~* Medical conditions, which, in the opinion of the investigators would jeopardize either the patient or the integrity of the data obtained.

- Gender: MALE
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: ACTIVE_COMPARATOR): POMELLA™ 2 x 500mg capsule once daily
- Group 2 (Type: PLACEBO_COMPARATOR): POMELLA™ placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).